Biotron Share Price Volatile as Investors Digest Latest Release

It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing.

Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors.

The Biotron share price is down from a high of $.445 on 17 October, 2018:

Biotron Share Price

Source: marketindex.com.au

Interested in bio-tech stocks but don’t know where to start? We’ve got a free report available here, that guides you through making the best picks.

Investors digesting new data from Biotron

For those of you with a biochemistry degree, the data can be found below:

Biotron Share Price

Source: biotron.com.au

 

Biotron Share Price

Source: biotron.com.au

Some highlights from the data include, a higher incidence of some side effects against placebo. These include headache, pyrexia (elevated body temperature), rash and rhinorrhoea (runny nose).

Additional quotes from the data include:

The BIT225 cohort had a significantly greater reduction of macrophage activation marker sCD163, a good indicator of all cause morbidity and mortality in HIV-2 patients. Additional reduction of this marker in patients taking BIT225 demonstrates significant immunological benefit.

 And:

The stimulation of the immune system in the BIT225 cohort makes this treatment approach a unique and potentially clinical beneficial step towards HIV-1 eradication.

Statistically significant results

As for the data itself, there were a number of statistically significant decreases for biomarker sCD163, statistically significant CD8* response, and statistically significant sustained delay in decline of CD4*.

To conclude, it is worth stressing that this is a Phase 2 trial, and the researchers are still trying to understand their own medicine.

Investors will be hoping ongoing investigations prove positive.

Regards,

Lachlann Tierney,
For Money Morning

PS: Learn how to pick the best bio-tech stocks with our free report. The download is available right here.

 


Lachlann Tierney is a writer for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest their money wisely. Recently he has been working with Ryan Dinse. Ryan is involved in three publications:


Leave a Reply

Your email address will not be published. Required fields are marked *

Money Morning Australia